Next-Generation Follicular Lymphoma Treatments: 50+ Pipeline Drugs from 45+ Global Companies Revealed in 2026 Report, analyses DelveInsight

DelveInsight's report titled "Follicular Lymphoma Pipeline Insight, 2026" delivers extensive insights into the follicular lymphoma drug development landscape, covering over 45 companies and more than 50 investigational therapies currently being explored. The report analyzes detailed profiles of pipeline drugs, including both clinical-stage and preclinical candidates. It also evaluates therapies based on product type, development stage, route of administration, and molecule classification, while additionally highlighting discontinued or inactive assets in the follicular lymphoma development ecosystem.

Request a sample and explore the latest progress in follicular lymphoma treatment drugs @
https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the Follicular Lymphoma Pipeline Report
• On January 20, 2026, AstraZeneca announced the initiation of a Phase III, multicenter, open-label clinical trial assessing the efficacy, safety, and clinical benefit of Surovatamig (AZD0486) combined with rituximab versus the investigator's choice of three standard immunochemotherapy regimens in patients with previously untreated follicular lymphoma.
• On January 12, 2026, BeiGene conducted a clinical study designed to compare the effectiveness of zanubrutinib plus obinutuzumab against lenalidomide combined with rituximab (R2) in patients with relapsed or refractory follicular lymphoma. The primary outcome is progression-free survival (PFS) evaluated by an independent review committee based on the 2014 International Working Group criteria for non-Hodgkin lymphoma, using PET/CT imaging. The trial also evaluates zanubrutinib plus rituximab versus R2 in patients with relapsed or refractory marginal zone lymphoma.
• On January 09, 2026, Genmab launched a clinical trial to determine the optimal dosing regimen for epcoritamab. The first phase focuses on identifying the most suitable dose, while the second phase assesses the selected dose in a broader population of B-cell non-Hodgkin lymphoma patients. Participants receive epcoritamab either as monotherapy or in combination with standard treatment regimens, across a range of treatment cohorts.
• Also on January 09, 2026, Regeneron Pharmaceuticals initiated a clinical study evaluating odronextamab, an investigational therapy, in combination with lenalidomide. The trial targets patients diagnosed with follicular lymphoma or marginal zone lymphoma whose disease has either relapsed after treatment or proven refractory to prior therapies. Both FL and MZL represent subtypes of non-Hodgkin lymphoma.
• On January 09, 2026, Hoffmann-La Roche began a clinical study assessing the efficacy and safety of mosunetuzumab combined with lenalidomide compared with rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have previously received at least one systemic treatment.
• On January 08, 2026, Celgene announced a Phase II randomized open-label study evaluating the safety and effectiveness of golcadomide in combination with rituximab in patients diagnosed with advanced-stage follicular lymphoma.
• DelveInsight's follicular lymphoma pipeline evaluation highlights a highly active therapeutic landscape, with 45+ pharmaceutical and biotechnology companies working on more than 50 novel therapies aimed at improving treatment outcomes.
• Key companies involved in follicular lymphoma drug development include Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron Pharmaceuticals, Pfizer, TriSalus Life Sciences, BeiGene, and several others.
• Notable pipeline therapies under development include DRL_RI (proposed rituximab biosimilar), MabThera®, epcoritamab, rituximab, lenalidomide, and additional investigational treatments.

Learn more about the follicular lymphoma therapeutic pipeline assessment @
Follicular Lymphoma Preclinical and Discovery Stage Products @
https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Follicular Lymphoma Pipeline Report Overview
The Follicular Lymphoma Pipeline Report offers a comprehensive understanding of the disease landscape, the current pipeline scenario, and an in-depth therapeutic evaluation of key investigational drugs. The report also identifies major unmet medical needs and potential opportunities for innovation in follicular lymphoma treatment.

Follicular Lymphoma Disease Overview
Follicular lymphoma (FL) is an indolent form of non-Hodgkin lymphoma that originates from B lymphocytes, a crucial component of the immune system. The disease is characterized by the abnormal formation of lymphoid follicles within lymph nodes and other lymphatic tissues.
Representing nearly 20% of all non-Hodgkin lymphoma cases, follicular lymphoma typically manifests with painless enlargement of lymph nodes. In later stages, patients may experience symptoms such as fatigue, night sweats, and unexplained weight loss.
Although FL is generally considered slow-progressing, it has the potential to transform into a more aggressive lymphoma subtype, making continuous monitoring essential. Advances in targeted therapies, immunotherapy, and precision medicine approaches have significantly improved patient outcomes and expanded available treatment options.

Emerging Drugs in the Follicular Lymphoma Pipeline
MIL62: Mab Works
MIL62 is a third-generation anti-CD20 monoclonal antibody designed to offer a strong competitive advantage in the treatment of B-cell malignancies. It represents the first domestically developed third-generation anti-CD20 antibody to enter Phase III registration trials in China.
Developed using Mab Works' ADCC-enhanced antibody technology platform, MIL62 has demonstrated superior antibody-dependent cellular cytotoxicity and antitumor activity compared with first-generation antibodies like rituximab and other third-generation agents such as obinutuzumab in both in vitro and in vivo studies.
The company is pursuing regulatory approval from the National Medical Products Administration (NMPA) for treating relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma. Simultaneously, clinical development programs are exploring its use in previously untreated patients, representing a larger patient population. The therapy is currently in Phase III clinical development for follicular lymphoma.

AZD0486: AstraZeneca
AZD0486, also known as TNB-486, is a bispecific antibody targeting CD19 and CD3 designed to stimulate T-cell-mediated destruction of malignant B cells in patients with relapsed or refractory follicular lymphoma.
The therapy works by activating T-cells to attack cancerous B-cells while incorporating a low-affinity anti-CD3 component, which helps reduce the risk of cytokine release syndrome (CRS), a common adverse effect associated with T-cell engaging therapies.
This design enables a controlled immune response, potentially improving the therapy's safety and tolerability profile. AZD0486 is currently being investigated in Phase III clinical trials for follicular lymphoma treatment.

Abexinostat: Xynomic Pharmaceuticals
Abexinostat is a potent oral pan-histone deacetylase inhibitor (HDAC inhibitor) developed by Xynomic Pharmaceuticals. Administered through a twice-daily dosing regimen, the therapy is designed to maintain optimal antitumor drug levels.
By targeting multiple HDAC enzymes, abexinostat promotes chromatin remodeling and gene expression changes that lead to cancer cell apoptosis, cell cycle arrest, and inhibition of angiogenesis.
Additionally, the drug acts as a Rad51 recombinase inhibitor, disrupting DNA repair processes and enhancing its anticancer activity. Abexinostat is currently in Phase II clinical trials for follicular lymphoma.

ABBV-319: AbbVie
ABBV-319 is a CD19-targeting antibody-drug conjugate (ADC) engineered to reduce glucocorticoid-associated toxicities while delivering enhanced therapeutic efficacy through three distinct mechanisms of action.
These include targeted delivery of a glucocorticoid receptor modulator payload, inhibition of CD19 signaling, and enhanced immune system engagement through Fc-mediated effector functions enabled by antibody afucosylation.
The therapy is presently in Phase I clinical development for follicular lymphoma treatment.

NX-2127: Nurix Therapeutics
NX-2127 is an orally administered small-molecule degrader targeting Bruton's tyrosine kinase (BTK) as well as cereblon neosubstrates IKZF1 and IKZF3.
Cereblon-modulating agents such as lenalidomide and pomalidomide are already approved for several hematologic cancers. NX-2127 aims to combine BTK degradation with immunomodulatory effects, potentially delivering stronger therapeutic responses in B-cell malignancies.
Early clinical data show activity in tumors carrying wild-type BTK as well as mutation-driven resistance variants, along with effective BTK degradation through once-daily oral dosing. The therapy is currently undergoing Phase I clinical evaluation.

Explore the evolving landscape of oncology drug development with DelveInsight's Follicular Lymphoma Pipeline Insights report. Download the report today to stay updated on the latest therapeutic breakthroughs - Follicular Lymphoma Treatment Drugs @
https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Insights Covered in the Follicular Lymphoma Pipeline Report
• The report offers comprehensive insights into pharmaceutical companies actively developing follicular lymphoma therapies, including the total number of drug candidates being investigated by each organization.
• It categorizes therapeutic candidates across early, mid, and late stages of clinical development, enabling stakeholders to evaluate the maturity of the development pipeline.
• The report also highlights companies engaged in targeted therapy development, including both active projects and inactive or discontinued programs.
• Additionally, it provides a detailed evaluation of drugs based on development stage, route of administration, molecular type, therapeutic target, treatment modality (monotherapy or combination), and mechanism of action.
• Another key component of the report is the analysis of strategic collaborations, licensing agreements, and investment activities, including partnerships between pharmaceutical companies and academic institutions aimed at accelerating drug development.

Follicular Lymphoma Companies
Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron Pharmaceuticals, Pfizer, TriSalus Life Sciences, BeiGene, and others.

Therapeutic Assessment by Route of Administration
Pipeline therapies are categorized based on the following administration routes:
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Therapeutic Assessment by Molecule Type
Pipeline products are also classified according to molecule type, including:
• Recombinant fusion proteins
• Small molecules
• Monoclonal antibodies
• Peptides
• Polymers
• Gene therapies

Learn more about the clinical development landscape and emerging therapies - Follicular Lymphoma Clinical Trials Assessment @
https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Follicular Lymphoma Pipeline Report
• Coverage: Global
• Key Companies: Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron Pharmaceuticals, Pfizer, TriSalus Life Sciences, BeiGene, and others.
• Key Pipeline Therapies: DRL_RI (rituximab biosimilar), MabThera®, epcoritamab, rituximab, lenalidomide, and others.
• Therapeutic evaluation includes analysis by product type (monotherapy, combination therapy) and clinical stage (discovery, preclinical, Phase I, Phase II, Phase III).

Curious to know which companies are leading follicular lymphoma drug discovery?
Download the report now and stay ahead in pharmaceutical innovation @ Follicular Lymphoma Emerging Drugs and Companies @
https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.